Brokerages Set Organon & Co. (NYSE:OGN) Price Target at $20.80

Shares of Organon & Co. (NYSE:OGN) have received an average rating of “Hold” from the seven analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $20.60.

OGN has been the subject of several analyst reports. Barclays reduced their target price on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 14th. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Morgan Stanley decreased their price objective on shares of Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating for the company in a report on Wednesday.

Organon & Co. Stock Up 8.1 %

Organon & Co. stock opened at $12.60 on Friday. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 1-year low of $11.05 and a 1-year high of $23.10. The firm’s fifty day simple moving average is $14.78 and its 200-day simple moving average is $15.78. The company has a market capitalization of $3.25 billion, a P/E ratio of 3.78, a P/E/G ratio of 0.90 and a beta of 0.73.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Sell-side analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Stockholders of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 8.89%. Organon & Co.’s dividend payout ratio is 33.63%.

Hedge Funds Weigh In On Organon & Co.

Large investors have recently bought and sold shares of the stock. Horizon Bancorp Inc. IN lifted its stake in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after buying an additional 1,585 shares during the period. Millstone Evans Group LLC bought a new stake in shares of Organon & Co. in the 4th quarter worth approximately $29,000. Larson Financial Group LLC grew its holdings in shares of Organon & Co. by 345.4% during the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock worth $33,000 after purchasing an additional 1,734 shares in the last quarter. Riverview Trust Co grew its holdings in shares of Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock worth $36,000 after purchasing an additional 1,292 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in shares of Organon & Co. by 92.2% during the fourth quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock valued at $41,000 after purchasing an additional 1,324 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.